致病性/可能致病性体细胞 CDK12 突变与黑人男性前列腺癌。
Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer.
机构信息
Tulane Cancer Center, Tulane University, New Orleans, LA, USA.
Medical Oncology, Mayo Clinic, Rochester, MN, USA.
出版信息
Oncologist. 2023 Nov 2;28(11):e1127-e1128. doi: 10.1093/oncolo/oyad240.
Abstract
Considering recently published data, this letter to the editor highlights the clinical relevance of CDK12 pathogenic or likely pathogenic mutations, noting that Black men have prostate cancers with increased rates of this pathologic alteration. Practitioners should be made aware of recent findings, given that CDK12 mutations are known to be associated with aggressive variants of prostate cancer and that they may confer susceptibility to PD-1 antagonists.
摘要
考虑到最近发表的数据，这封给编辑的信强调了 CDK12 致病性或可能致病性突变的临床相关性，并指出黑人男性的前列腺癌中这种病理改变的发生率增加。鉴于 CDK12 突变已知与前列腺癌的侵袭性变异有关，并且它们可能使患者易患 PD-1 拮抗剂，因此应让从业者了解最近的发现。
相似文献
1
Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer.致病性/可能致病性体细胞 CDK12 突变与黑人男性前列腺癌。
Oncologist. 2023 Nov 2;28(11):e1127-e1128. doi: 10.1093/oncolo/oyad240.
2
In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer".针对“前列腺癌黑人男性中的致病性/可能致病性体细胞 CDK12 突变”的回复。
Oncologist. 2023 Nov 2;28(11):e1129-e1130. doi: 10.1093/oncolo/oyad264.
3
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.周期蛋白依赖性激酶 12 突变型晚期前列腺癌的临床结局。
Eur Urol. 2020 Mar;77(3):333-341. doi: 10.1016/j.eururo.2019.09.036. Epub 2019 Oct 20.
4
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.CDK12 突变在前列腺癌中的预后和临床病理价值：一项荟萃分析。
Expert Rev Anticancer Ther. 2023 Feb;23(2):207-216. doi: 10.1080/14737140.2023.2168647. Epub 2023 Feb 3.
5
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.CDK12 失活定义了一类独特的免疫原性晚期前列腺癌。
Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034.
6
Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.描述 CDK12 改变的侵袭性前列腺癌：十二例病例系列。
Int J Clin Oncol. 2022 Dec;27(12):1867-1873. doi: 10.1007/s10147-022-02248-z. Epub 2022 Oct 21.
7
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.泛癌分析 CDK12 改变鉴定出具有独特基因组和临床特征的前列腺癌亚群。
Eur Urol. 2020 Nov;78(5):671-679. doi: 10.1016/j.eururo.2020.03.024. Epub 2020 Apr 19.
8
A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.一种新的胚系 EGFR 变异 p.R831H 导致 CDK12 突变前列腺癌伴串联重复表型的家族易感性。
Oncogene. 2020 Oct;39(44):6871-6878. doi: 10.1038/s41388-020-01476-9. Epub 2020 Sep 25.
9
, , and Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.、 和 缺陷以不同方式塑造前列腺肿瘤驱动基因组学和临床侵袭性。
Clin Cancer Res. 2021 Mar 15;27(6):1650-1662. doi: 10.1158/1078-0432.CCR-20-3708. Epub 2021 Jan 7.
10
CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?前列腺癌中的CDK12基因改变：现状如何，但在临床上是否具有可操作性？
Eur Urol. 2020 Nov;78(5):680-681. doi: 10.1016/j.eururo.2020.04.007. Epub 2020 May 4.
引用本文的文献
1
Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer.美国转移性前列腺癌退伍军人的体细胞肿瘤下一代测序
JAMA Netw Open. 2025 May 1;8(5):e259119. doi: 10.1001/jamanetworkopen.2025.9119.
2
Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing.接受体细胞肿瘤二代测序的美国转移性前列腺癌退伍军人的致癌性改变、种族与生存情况
bioRxiv. 2024 Oct 25:2024.10.24.620071. doi: 10.1101/2024.10.24.620071.
3
In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer".针对“前列腺癌黑人男性中的致病性/可能致病性体细胞 CDK12 突变”的回复。
Oncologist. 2023 Nov 2;28(11):e1129-e1130. doi: 10.1093/oncolo/oyad264.
本文引用的文献
1
Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.综合基因组分析与不同种族晚期前列腺癌的治疗模式：一项大规模回顾性分析。
Lancet Digit Health. 2023 Jun;5(6):e380-e389. doi: 10.1016/S2589-7500(23)00053-5.
2
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.比较阿非利加裔美国人和高加索裔转移性去势抵抗性前列腺癌患者在接受阿比特龙和/或恩扎鲁胺治疗后的循环肿瘤 DNA。
Prostate. 2023 Aug;83(11):1028-1034. doi: 10.1002/pros.24544. Epub 2023 Apr 27.
3
Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans.美国黑人和白人退伍军人前列腺癌中的可操作基因组改变。
Oncologist. 2023 Jun 2;28(6):e473-e477. doi: 10.1093/oncolo/oyad042.
4
-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.- 前列腺癌改变：标准全身疗法、聚（ADP - 核糖）聚合酶抑制剂和PD - 1抑制剂的临床特征及治疗结果
JCO Precis Oncol. 2020;4:370-381. doi: 10.1200/po.19.00399. Epub 2020 Apr 21.
Zotero 插件